These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone. Xu C Endocrine; 2024 Feb; 83(2):285-301. PubMed ID: 37847370 [TBL] [Abstract][Full Text] [Related]
25. New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option? Gromotowicz-Poplawska A; Szoka P; Kolodziejczyk P; Kramkowski K; Wojewodzka-Zelezniakowicz M; Chabielska E Exp Biol Med (Maywood); 2016 Nov; 241(17):1888-1899. PubMed ID: 27439538 [TBL] [Abstract][Full Text] [Related]
26. Mitigating risk of aldosterone in diabetic kidney disease. Frimodt-Møller M; Persson F; Rossing P Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):145-151. PubMed ID: 31599747 [TBL] [Abstract][Full Text] [Related]
27. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648 [TBL] [Abstract][Full Text] [Related]
28. Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population. Abdel Ghafar MT Clin Exp Hypertens; 2019; 41(8):779-786. PubMed ID: 30561227 [No Abstract] [Full Text] [Related]
29. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Lea WB; Kwak ES; Luther JM; Fowler SM; Wang Z; Ma J; Fogo AB; Brown NJ Kidney Int; 2009 May; 75(9):936-44. PubMed ID: 19225557 [TBL] [Abstract][Full Text] [Related]
35. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Connell JM; MacKenzie SM; Freel EM; Fraser R; Davies E Endocr Rev; 2008 Apr; 29(2):133-54. PubMed ID: 18292466 [TBL] [Abstract][Full Text] [Related]
36. Dietary potassium supplementation and sodium restriction stimulate aldosterone synthase but not 11 beta-hydroxylase P-450 messenger ribonucleic acid accumulation in rat adrenals and require angiotensin II production. Tremblay A; Parker KL; Lehoux JG Endocrinology; 1992 Jun; 130(6):3152-8. PubMed ID: 1597135 [TBL] [Abstract][Full Text] [Related]
37. The angiotensin type 2 receptor in the human adrenocortical zona glomerulosa and in aldosterone-producing adenoma: low expression and no functional role. Vanderriele PE; Caroccia B; Seccia TM; Piazza M; Lenzini L; Torresan F; Iacobone M; Unger T; Rossi GP Clin Sci (Lond); 2018 Mar; 132(6):627-640. PubMed ID: 29436482 [TBL] [Abstract][Full Text] [Related]
39. Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1. Takeda Y; Demura M; Kometani M; Karashima S; Yoneda T; Takeda Y Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982850 [TBL] [Abstract][Full Text] [Related]
40. A patent review of aldosterone synthase inhibitors (2014-present). Wu J; Ding X; Tan X Expert Opin Ther Pat; 2022 Jan; 32(1):13-28. PubMed ID: 34365871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]